Engineered hyaluronic acid-decorated niosomal nanoparticles for controlled and targeted delivery of epirubicin to treat breast cancer

Mansoori-Kermani, Amirreza; Khalighi, Sadaf; Akbarzadeh, Iman; Niavol, Fazeleh Ranjbar; Motasadizadeh, Hamidreza; Mahdieh, Athar; Jahed, Vahid; Abdinezhad, Masoud; Rahbariasr, Nikoo; Hosseini, Mahshid; Ahmadkhani, Nima; Panahi, Behnam; Fatahi, Yousef; Mozafari, Masoud; Kumar, Alan Prem; Mostafavi, Ebrahim

doi:10.1016/j.mtbio.2022.100349

Cited by 37 publications

(17 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…30 Niosomes as nonionic surfactants have been widely studied due to their advantages including biodegradability, biocompatibility, low immunogenicity, long shelf life, high stability, and allow drug delivery to the target site at a controlled release rate. [31][32][33] Aqueous solubility and oral bioavailability of niosomal Candesartan cilexetil, a commercially marketed compound with low bioavailability (15%), was significantly enhanced. 34 In a study, PEGylated niosomal vincristine showed potent in vitro toxicity in B-cell lymphoma cancer cells.…”

Section: Introductionmentioning

confidence: 99%

In vitro Development of Controlled-Release Nanoniosomes for Improved Delivery and Anticancer Activity of Letrozole for Breast Cancer Treatment

Ahmadi¹,

Seraj²,

Chiani³

et al. 2022

IJN

Self Cite

View full text Add to dashboard Cite

Introduction Breast cancer is among the most prevalent mortal cancers in women worldwide. In the present study, an optimum formulation of letrozole, letrozole-loaded niosome, and empty niosome was developed, and the anticancer effect was assessed in in vitro MCF-7, MCF10A and MDA-MB-231 breast cancer cell lines. Materials and Methods Various niosomal formulations of letrozole were fabricated through thin-film hydration method and characterized in terms of size, polydispersity index (PDI), morphology, entrapment efficiency (EE%), release kinetics, and stability. Optimized niosomal formulation of letrozole was achieved by response surface methodology (RSM). Antiproliferative activity and the mechanism were assessed by MTT assay, quantitative real-time PCR, and flow cytometry. Furthermore, cellular uptake of optimum formulation was evaluated by confocal electron microscopy. Results The formulated letrozole had a spherical shape and showed a slow-release profile of the drug after 72 h. The size, PDI, and eEE% of nanoparticles showed higher stability at 4°C compared with 25°C. The drug release from niosomes was in accordance with Korsmeyer–Peppa’s kinetic model. Confocal microscopy revealed the localization of drug-loaded niosomes in the cancer cells. MTT assay revealed that all samples exhibited dose-dependent cytotoxicity against breast cancer cells. The IC 50 of mixed formulation of letrozole with letrozole-loaded niosome (L + L 3 ) is the lowest value among all prepared formulations. L+L 3 influenced the gene expression in the tested breast cancer cell lines by down-regulating the expression of Bcl 2 gene while up-regulating the expression of p53 and Bax genes. The flow cytometry results revealed that L + L 3 enhanced the apoptosis rate in both MCF-7 and MDA-MB-231 cell lines compared with the letrozole (L), letrozole-loaded niosome (L 3 ), and control sample. Conclusion Results indicated that niosomes could be a promising drug carrier for the delivery of letrozole to breast cancer cells.

show abstract

Section: Introductionmentioning

confidence: 99%

In vitro Development of Controlled-Release Nanoniosomes for Improved Delivery and Anticancer Activity of Letrozole for Breast Cancer Treatment

Ahmadi¹,

Seraj²,

Chiani³

et al. 2022

IJN

Self Cite

View full text Add to dashboard Cite

show abstract

“…The niosomes appeared as small spherical vesicles in the case of F1, while coating with hyaluronic acid not only increased the size (F2) but also reduced the sphericity of niosomes (F2 and F4). The deviation from the circular shape of hyaluronic acid-coated niosomes was attributed to the combination of hydration, surface charge modification, intermolecular interaction, and osmotic effects, collectively leading to a change in the shape with deformation in their circular shape . The use of two surfactants (Span 80 and Tween 80) in formulation F3 causes the agglomeration of vesicles.…”

Section: Resultsmentioning

confidence: 99%

“…The deviation from the circular shape of hyaluronic acidcoated niosomes was attributed to the combination of hydration, surface charge modification, intermolecular interaction, and osmotic effects, collectively leading to a change in the shape with deformation in their circular shape. 16 The use of two surfactants (Span 80 and Tween 80) in formulation F3 causes the agglomeration of vesicles. It was observed that the coated formulation (F2) with hyaluronic acid produces largersize, tubular-shaped, and segregated particles (Figure 1).…”

Section: Surface Morphologymentioning

confidence: 99%

See 1 more Smart Citation

5-Fluorouracil-Loaded Hyaluronic Acid-Coated Niosomal Vesicles: Fabrication and Ex Vivo Evaluation for Skin Drug Delivery

Khalid,

Shah,

Saeed

et al. 2023

ACS Omega

View full text Add to dashboard Cite

“…Cancer is a significant universal health issue and one of the leading death causes in the world . Natural resources such as plants have long been considered as a source of chemotherapeutic or chemopreventive agents against cancer. − However, due to the increasing resistance of certain tumors and the severe side effects of conventional chemotherapy, new pharmacological molecules are needed.…”

Section: Introductionmentioning

confidence: 99%

Use of Saponinosomes from Ziziphus spina-christi as Anticancer Drug Carriers

et al. 2022

Self Cite

View full text Add to dashboard Cite

Saponins are plant glycosides with different structures and biological activities, such as anticancer effects. Ziziphus spina-christi is a plant rich in saponin, and this compound is used to treat malignant melanoma in the present study. Nanophytosomes can be used as an advantageous nanodrug delivery system for plant extracts. The aim of this work is to use the saponin-rich fraction (SRF) from Z. spina-christi and prepare SRF-loaded nanophytosomes (saponinosomes) and observe the in vitro and in vivo effects of these carriers. First, the SRF was obtained from Z. spina-christi by a solvent–solvent fractionation method. Then, Fourier transform infrared (FTIR) analyses were performed to confirm the presence of saponins in the extracted material. Subsequently, the saponinosomes were prepared by the solvent injection method (ether injection method) using a 1:1:1 ratio of lecithin/cholesterol/SRF in the mixture. Characterization of the prepared saponinosomes was performed by FTIR, dynamic light scattering (DLS), field-emission scanning electron microscopy (FE-SEM), and atomic force microscopy (AFM) analyses. In addition, a UV–vis spectrophotometer was used to determine the entrapment efficiency (EE) and in vitro release of the SRF. Finally, cell cytotoxicity of the different formulations was evaluated using a 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay on both mouse melanoma cells (B16F10) and fibroblasts (L929). Using DLS, AFM, and FE-SEM analyses, the particle size was determined to be 58 ± 6 nm with a zeta potential of −32 ± 2 mV. The calculated EE was 85 ± 3%. The results of the in vitro release profile showed that 68.2% of the SRF was released from the saponinosome after 48 h. The results of the MTT assay showed that the SRF and saponinosomes have high toxicity on B16F10 melanoma cells, but saponinosomes showed a significant decrease in cytotoxicity on L929 fibroblast cells compared with that of the SRF. Our results indicate that the SRF from Z. spina-christi has anticancer activity, and the saponinosomes prepared in this work can control tumor growth, improve therapeutic efficacy, and reduce the side effects of saponins.

show abstract

Engineered hyaluronic acid-decorated niosomal nanoparticles for controlled and targeted delivery of epirubicin to treat breast cancer

Cited by 37 publications

References 70 publications

In vitro Development of Controlled-Release Nanoniosomes for Improved Delivery and Anticancer Activity of Letrozole for Breast Cancer Treatment

In vitro Development of Controlled-Release Nanoniosomes for Improved Delivery and Anticancer Activity of Letrozole for Breast Cancer Treatment

5-Fluorouracil-Loaded Hyaluronic Acid-Coated Niosomal Vesicles: Fabrication and Ex Vivo Evaluation for Skin Drug Delivery

Use of Saponinosomes from Ziziphus spina-christi as Anticancer Drug Carriers

Contact Info

Product

Resources

About